US FDA Marches Toward Record Novel Approvals With Ionis’ Tegsedi, Leadiant’s Revcovi
Complete response letter for Acacia’s Barhemsys is only rain on Oct. 5 approval parade.
You may also be interested in...
The RNA-drug developer, which is buying the approximately 24% of Akcea it doesn't already own for around $500m, highlighted the maturing pipeline in a cardiovascular overview.
Advisory Committee on Immunization Practices recommends vaccination based on shared clinical decision-making in individuals ages 27-45 years old – but says only those at high risk of contracting HPV are likely to benefit and should get the vaccine.
Keeping Track: US FDA Approves Pfizer’s Vyndaqel, Jacobus’ Ruzurgi, But Nixes Acacia’s Barhemsys Again
The latest drug development news and highlights from our US FDA Performance Tracker.